Mar 28, 2023 / 03:00PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thanks very much, everybody. It's my pleasure to be hosting the Amylyx team. We've got Josh; Justin; and Jim here. They're going to give kind of a brief update on Amylyx for about 15 minutes, and then we'll have 10 minutes at the end for Q&A. So like with prior analysts, feel free to type a question into the link or shoot me an e-mail, and I certainly have a whole list of my own.
So guys take it away, and thank you again for joining.
Justin B. Klee - Amylyx Pharmaceuticals, Inc. - Co-Founder, Co-CEO & Director
Well, thank you so much, Paul. Thanks, everyone, for joining. So as Paul said, we'll give a brief overview of Amylyx, who we are, and the latest and greatest, and then, yes, I'm very happy to take questions.
So first, just to start, I think we're a really mission-focused company. We're focused in neurodegenerative disease but particularly ALS. So as you'll see through our presentation
Amylyx Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript
Mar 28, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers